These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 818390)

  • 1. Results of present-day therapy of Parkinson's disease.
    Stellar S; Bhandari Y
    J Med Soc N J; 1976 Apr; 73(4):313-7. PubMed ID: 818390
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's disease and long-term levodopa therapy.
    Bergmann KJ; Mendoza MR; Yahr MD
    Adv Neurol; 1987; 45():463-7. PubMed ID: 3103389
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermittent levodopa therapy in parkinsonism.
    Koller WC
    Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 6. The long-term effects of combining carbidopa with levodopa for Parkinson's disease.
    Lee MC; Lippert DM; Loewenson RB; Tolosa ES; Resch JA; Martin WE
    Trans Am Neurol Assoc; 1976; 101():262-4. PubMed ID: 829295
    [No Abstract]   [Full Text] [Related]  

  • 7. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 8. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dystonia and Parkinson's disease.
    Carella F; Giovannini P; Girotti F; Testa D; Caraceni T
    Adv Neurol; 1993; 60():558-61. PubMed ID: 8420191
    [No Abstract]   [Full Text] [Related]  

  • 10. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
    Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
    Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting drug holiday in Parkinson's disease.
    Bermejo F; Calandre L; Molina JA; Martinez P; De Yebenes JG
    Adv Neurol; 1987; 45():503-6. PubMed ID: 3103392
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L; Bracco F; Saladini M
    J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 19. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
    Lieberman AN; Gopinathan G; Pasternack P; Goldstein M
    Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.